204 related articles for article (PubMed ID: 22331316)
21. [New system combining Hyams grading system and modified Kadish stage to evaluate the progress of esthesioneuroblastoma].
Lai YY; Lin TJ; Jiang LJ; Deng J; Zuo KJ; Zhang Y; Shi JB
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jul; 33(7):599-602. PubMed ID: 31327194
[No Abstract] [Full Text] [Related]
22. Esthesioneuroblastoma: updating histologic grading as it relates to prognosis.
Gallagher KK; Spector ME; Pepper JP; McKean EL; Marentette LJ; McHugh JB
Ann Otol Rhinol Laryngol; 2014 May; 123(5):353-8. PubMed ID: 24668054
[TBL] [Abstract][Full Text] [Related]
23. Treatment modalities and outcomes of olfactory neuroblastoma.
Song CM; Won TB; Lee CH; Kim DY; Rhee CS
Laryngoscope; 2012 Nov; 122(11):2389-95. PubMed ID: 23070733
[TBL] [Abstract][Full Text] [Related]
24. Expression patterns of Trk-A, Trk-B, GRP78, and p75NRT in olfactory neuroblastoma.
Weinreb I; Goldstein D; Irish J; Perez-Ordonez B
Hum Pathol; 2009 Sep; 40(9):1330-5. PubMed ID: 19386345
[TBL] [Abstract][Full Text] [Related]
25. Consolidating the Hyams grading system in esthesioneuroblastoma - an individual participant data meta-analysis.
Vuong HG; Ngo TNM; Dunn IF
J Neurooncol; 2021 May; 153(1):15-22. PubMed ID: 33770323
[TBL] [Abstract][Full Text] [Related]
26. Patient characteristics of olfactory neuroblastoma: experience from a tertiary cancer centre 2000-2016 covering Eastern Denmark.
Gram SB; Grønhøj C; Mann H; Jakobsen KK; Kiss K; Bilde A; von Buchwald C
APMIS; 2018 Aug; 126(8):663-666. PubMed ID: 30168622
[TBL] [Abstract][Full Text] [Related]
27. Olfactory neuroblastoma (esthesioneuroblastoma) and esthesioneuroepithelioma: histologic and immunohistochemical study.
Taraszewska A; Czorniuk-Sliwa A; Dambska M
Folia Neuropathol; 1998; 36(2):81-6. PubMed ID: 9757618
[TBL] [Abstract][Full Text] [Related]
28. Expression of bcl-2 is associated with microvessel density in olfactory neuroblastoma.
Diensthuber M; Potinius M; Rodt T; Stan AC; Welkoborsky HJ; Samii M; Schreyögg J; Lenarz T; Stöver T
J Neurooncol; 2008 Sep; 89(2):131-9. PubMed ID: 18431543
[TBL] [Abstract][Full Text] [Related]
29. Esthesioneuroblastoma - a clinicopathologic study and role of DNA topoisomerase alpha.
Sharma S; Sharma MC; Johnson MH; Lou M; Thakar A; Sarkar C
Pathol Oncol Res; 2007; 13(2):123-9. PubMed ID: 17607373
[TBL] [Abstract][Full Text] [Related]
30. Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors.
Jethanamest D; Morris LG; Sikora AG; Kutler DI
Arch Otolaryngol Head Neck Surg; 2007 Mar; 133(3):276-80. PubMed ID: 17372086
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience.
McElroy EA; Buckner JC; Lewis JE
Neurosurgery; 1998 May; 42(5):1023-7; discussion 1027-8. PubMed ID: 9588546
[TBL] [Abstract][Full Text] [Related]
32. Esthesioneuroblastoma--what is the optimal treatment?
Eriksen JG; Bastholt L; Krogdahl AS; Hansen O; Joergensen KE
Acta Oncol; 2000; 39(2):231-5. PubMed ID: 10859017
[TBL] [Abstract][Full Text] [Related]
33. [Clinicopathologic study of sinonasal teratocarcinosarcoma and its contrast with olfactory neuroblastoma].
Li X; Liu HG; Xie XJ; Han YD; Li M
Zhonghua Bing Li Xue Za Zhi; 2008 Jul; 37(7):458-64. PubMed ID: 19035117
[TBL] [Abstract][Full Text] [Related]
34. Prognosis and biology in esthesioneuroblastoma: the emerging role of Hyams grading system.
Saade RE; Hanna EY; Bell D
Curr Oncol Rep; 2015 Jan; 17(1):423. PubMed ID: 25416317
[TBL] [Abstract][Full Text] [Related]
35. Calretinin staining facilitates differentiation of olfactory neuroblastoma from other small round blue cell tumors in the sinonasal tract.
Wooff JC; Weinreb I; Perez-Ordonez B; Magee JF; Bullock MJ
Am J Surg Pathol; 2011 Dec; 35(12):1786-93. PubMed ID: 22020045
[TBL] [Abstract][Full Text] [Related]
36. Esthesioneuroblastoma: a Danish clinicopathological study of 40 consecutive cases.
Ingeholm P; Theilgaard SA; Buchwald C; Hansen HS; Francis D
APMIS; 2002 Sep; 110(9):639-45. PubMed ID: 12529017
[TBL] [Abstract][Full Text] [Related]
37. Combined modality therapy of esthesioneuroblastoma.
McLean JN; Nunley SR; Klass C; Moore C; Müller S; Johnstone PA
Otolaryngol Head Neck Surg; 2007 Jun; 136(6):998-1002. PubMed ID: 17547995
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic Features and Prognosis of Olfactory Neuroblastoma with Isocitrate Dehydrogenase 2 Mutations.
Wu L; An J; Liu H
World Neurosurg; 2022 Mar; 159():e23-e31. PubMed ID: 34856401
[TBL] [Abstract][Full Text] [Related]
39. Patterns of failure and outcome in esthesioneuroblastoma.
Dias FL; Sa GM; Lima RA; Kligerman J; Leoncio MP; Freitas EQ; Soares JR; Arcuri RA
Arch Otolaryngol Head Neck Surg; 2003 Nov; 129(11):1186-92. PubMed ID: 14623748
[TBL] [Abstract][Full Text] [Related]
40. Olfactory neuroblastoma in dogs and cats--a histological and immunohistochemical analysis.
Brosinski K; Janik D; Polkinghorne A; Von Bomhard W; Schmahl W
J Comp Pathol; 2012; 146(2-3):152-9. PubMed ID: 21783199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
